

## Brilliant Violet 421™ anti-mouse Ly-6G Antibody

<b>Catalog# / Size</b>	127627 / 125 µL 127628 / 50 µg
<b>Clone</b>	1A8
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	Lymphocyte antigen 6 complex, locus G
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Ly-6G transfected EL-4J cell line.
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
<b>Concentration</b>	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">IHC-F - Verified</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.</p> <p><a href="#">Learn more about Brilliant Violet™.</a></p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
<b>Excitation Laser</b>	Violet Laser (405 nm)
<b>Application Notes</b>	<p>While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C<sup>15</sup>. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8<sup>15</sup>. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4<sup>16</sup>.</p> <p>Additional reported applications (for the relevant formats) include: immunohistochemistry<sup>9</sup> of frozen</p>

sections<sup>10</sup> and paraffin-embedded sections<sup>11</sup>, depletion<sup>4, 12-14</sup>, and spatial biology (IBEX)<sup>20,21</sup>. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for *in vivo* studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).

## Application References

(PubMed link indicates BioLegend citation)

1. Fleming TJ, *et al.* 1993. *J. Immunol.* 151:2399. (FC)
2. Daley JM, *et al.* 2008. *J. Leukocyte Biol.* 83:1. (FC)
3. Dietlin TA, *et al.* 2007. *J. Leukocyte Biol.* 81:1205. (FC)
4. Daley J, *et al.* 2007. *J. Leukocyte Biol.* doi:10.1189. (Deplete) [PubMed](#)
5. Tadagavadi RK, *et al.* 2010. *J. Immunol.* 185:4904. [PubMed](#)
6. Sumagin R, *et al.* 2010. *J. Immunol.* 185:7057. [PubMed](#)
7. Guiducci C, *et al.* 2010. *J. Exp Med.* 207:2931. [PubMed](#)
8. Fujita M, *et al.* 2011. *Cancer Res.* 71:2664. [PubMed](#)
9. Van Leeuwen, *et al.* 2008. *Arterioscler. Thromb. Vasc. Biol.* 28:84. (IHC)
10. Kowanetz M, *et al.* 2010. *P. Natl. Acad. Sci. USA* 107:21248. [supplementary data] (IHC)
11. Esbona K, *et al.* 2016. *Breast Cancer Res.* 18:35. (IHC)
12. Wojtasiak M, *et al.* 2010. *J. Gen. Virol.* 91:2158. (FC, Deplete)
13. Jaeger BN, *et al.* 2012. *J. Exp. Med.* 209:565. (Deplete)
14. Wozniak KL, *et al.* 2012. *BMC Immunol.* 13:65 (FC, Deplete)
15. Ribechini E, *et al.* 2009. *Eur. J. Immunol.* 39:3538.
16. Ng LG, *et al.* 2011. *J Invest. Dermatol.* 131:2058. [PubMed](#)
17. Ma C, *et al.* 2012. *J. Leukoc. Biol.* 92:1199.
18. McCartney-Francis, N, *et al.* 2014. *J Leukoc. Biol.* 96:917. [PubMed](#)
19. Her Z, *et al.* 2014. *EMBO Mol. Med.* 7:24. [PubMed](#)
20. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
21. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

## Product Citations

1. Hutter K, *et al.* 2022. *Front Immunol.* 13:967914. [PubMed](#)
2. Wilden A, *et al.* 2022. *Front Immunol.* 13:991295. [PubMed](#)
3. Jong RM, *et al.* 2022. *J Immunol.* 208:407. [PubMed](#)
4. Radovanovic I, *et al.* 2014. *J Immunol.* 193:1290. [PubMed](#)
5. Minutti CM, *et al.* 2019. *Immunity.* 50:645. [PubMed](#)
6. Mansouri N, *et al.* 2019. *JCI Insight.* 4:e128060. [PubMed](#)
7. Wang L, *et al.* 2020. *Cells.* 0.458333333. [PubMed](#)
8. Piepke M, *et al.* 2021. *J Neuroinflammation.* 18:265. [PubMed](#)
9. Khamissi FZ, *et al.* 2022. *Sci Adv.* 8:eabm5900. [PubMed](#)
10. Han H, *et al.* 2021. *Front Pharmacol.* 12:726586. [PubMed](#)
11. Park JG, *et al.* 2021. *iScience.* 24(9):102941. [PubMed](#)
12. Gu H, *et al.* 2021. *Immun Inflamm Dis.* 9:1686. [PubMed](#)
13. Brandt S, *et al.* 2020. *J Am Soc Nephrol.* 31:2589. [PubMed](#)
14. Pan H, *et al.* 2020. *Mol Psychiatry.* . [PubMed](#)
15. Glaubitz J, *et al.* 2022. *Nat Commun.* 13:4502. [PubMed](#)
16. Wang LT, *et al.* 2021. *STAR Protocols.* 2(1):100337. [PubMed](#)
17. Angelidis I, *et al.* 2019. *Nat Commun.* 10:963. [PubMed](#)
18. Lee RD, *et al.* 2021. *Nat Commun.* 12:6843. [PubMed](#)
19. Ma M, *et al.* 2021. *Front Immunol.* 12:718779. [PubMed](#)
20. Green DP, *et al.* 2019. *Neuron.* 101:412. [PubMed](#)
21. Peres-Emidio EC, *et al.* 2022. *Front Cell Infect Microbiol.* 12:811474. [PubMed](#)
22. Dane EL, *et al.* 2022. *Nat Mater.* 21:710. [PubMed](#)
23. Lissner MM, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
24. Jackson-Jones LH, *et al.* 2020. *Immunity.* 52:700. [PubMed](#)
25. Barman PK, *et al.* 2019. *J Immunol.* 202:2720. [PubMed](#)
26. Ajina R, *et al.* 2021. *Cancer Immunol Res.* 9:386. [PubMed](#)
27. Linehan JL *et al.* 2018. *Cell.* 172(4):784-796 . [PubMed](#)
28. Pereira JA, *et al.* 2020. *Hum Mol Genet.* 29:1253. [PubMed](#)
29. Baudoux T, *et al.* 2018. *Sci Rep.* 4.0375. [PubMed](#)
30. Morimoto A, *et al.* 2021. *Nat Commun.* 12:2136. [PubMed](#)
31. Ghandhi SA, *et al.* 2022. *Sci Rep.* 12:14124. [PubMed](#)
32. Yu Y, *et al.* 2022. *Nat Commun.* 13:6857. [PubMed](#)
33. Hassan AO, *et al.* 2021. *Cell Reports.* 36(4):109452. [PubMed](#)
34. Köhler D, *et al.* 2020. *Nat Commun.* 11:1315. [PubMed](#)
35. Liu T, *et al.* 2022. *Front Immunol.* 13:901349. [PubMed](#)
36. Holokai L, *et al.* 2020. *Cancers (Basel).* 12:00. [PubMed](#)
37. Macdougall CE *et al.* 2018. *Cell metabolism.* 27(3):588-601 . [PubMed](#)
38. Zeng Z, *et al.* 2022. *Oncogene.* .: [PubMed](#)
39. Li YN, *et al.* 2022. *Nat Commun.* 13:4074. [PubMed](#)
40. Murakami K, *et al.* 2021. *Cell Reports.* 34(1):108579. [PubMed](#)
41. Ni J, *et al.* 2020. *Immunity.* 52(6):1075-1087.e8. [PubMed](#)
42. Liyanage S, *et al.* 2016. *Exp Eye Res.* 151:160-70. [PubMed](#)
43. Kostadinova E, *et al.* 2016. *Sci Rep.* 6:30943. [PubMed](#)
44. Ermer D, *et al.* 2016. *PLoS Pathog.* 11: 1005043. [PubMed](#)
45. Pundir P, *et al.* 2020. *Cell Host & Microbe.* 26(1):114-122. [PubMed](#)
46. Andrade ACDSP, *et al.* 2021. *J Virol.* 95:e0127621. [PubMed](#)
47. Hasegawa T, *et al.* 2020. *Sci Rep.* 10:13480. [PubMed](#)
48. Zeng Q, *et al.* 2022. *iScience.* 25:105151. [PubMed](#)
49. Niderla-Bielinska J, *et al.* 2021. *Int J Mol Sci.* :22. [PubMed](#)
50. Wang LT, *et al.* 2020. *Cell Rep.* 32:108188. [PubMed](#)
51. Kullberg M, *et al.* 2015. *Nanomedicine.* 11: 1355-1363. [PubMed](#)

52. Muri J, *et al.* 2020. *eLife*. 9:e53627. [PubMed](#)
53. Xueyang Yu *et al.* 2017. *Immunity*. 47(5):903-912. [PubMed](#)
54. Olson B, *et al.* 2021. *Brain Behav Immun*. 97:102. [PubMed](#)
55. Alexander Mildner *et al.* 2017. *Immunity*. 46(5):849-862. [PubMed](#)
56. Rustenhoven J, *et al.* 2021. *Cell*. 184(4):1000-1016.e27. [PubMed](#)
57. Clemente-Casares X, *et al.* 2017. *Immunity*. 47:974. [PubMed](#)
58. Gardner P, *et al.* 2017. *Sci Rep*. 7:40830. [PubMed](#)
59. Xu W, *et al.* 2021. *Immunity*. 54(3):526-541.e7. [PubMed](#)
60. Morein D, *et al.* 2021. *Cells*. 10: [PubMed](#)
61. La Salvia S, *et al.* 2020. *Am J Physiol Renal Physiol*. 319:F868. [PubMed](#)
62. Bertuzzi M, *et al.* 2014. *PLoS Pathog*. 10:1004413. [PubMed](#)
63. Fransén Pettersson N, *et al.* 2018. *PLoS One*. 13:e0203228. [PubMed](#)
64. Fleskens V, *et al.* 2019. *Cell Rep*. 26:3600. [PubMed](#)
65. Harding CL, *et al.* 2020. *Front Cell Infect Microbiol*. 10:328. [PubMed](#)
66. Herbst S, *et al.* 2015. *EMBO Mol Med*. 30:240. [PubMed](#)
67. Nepal S, *et al.* 2019. *Proc Natl Acad Sci U S A*. 116:16513. [PubMed](#)
68. Zheng C, *et al.* 2021. *J Extracell Vesicles*. 10:e12109. [PubMed](#)
69. Li H, *et al.* 2021. *J Clin Invest*. 131: [PubMed](#)
70. Xiong S, *et al.* 2020. *J Clin Invest*. 130:3684. [PubMed](#)
71. Lau A, *et al.* 2022. *Sci Adv*. 8:eabm0142. [PubMed](#)
72. Kennedy J, *et al.* 2014. *J Exp Med*. 211:2519. [PubMed](#)

**RRID** AB\_10897944 (BioLegend Cat. No. 127627)  
 AB\_2562567 (BioLegend Cat. No. 127628)

## Antigen Details

---

<b>Structure</b>	A 21-35 kD GPI-anchored membrane protein
<b>Distribution</b>	Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.
<b>Cell Type</b>	Granulocytes, Macrophages, Monocytes
<b>Biology Area</b>	Immunology, Innate Immunity
<b>Antigen References</b>	Fleming TJ, <i>et al.</i> 1993. <i>J. Immunol.</i> 151:2399.
<b>Gene ID</b>	<a href="#">546644</a>

## Related Protocols

---

[Immunohistochemistry Protocol for Frozen Sections](#)

[Cell Surface Flow Cytometry Staining Protocol](#)


## Other Formats

---


Alexa Fluor® 594 anti-mouse Ly-6G, Purified anti-mouse Ly-6G, Biotin anti-mouse Ly-6G, FITC anti-mouse Ly-6G, PE anti-mouse Ly-6G, Alexa Fluor® 647 anti-mouse Ly-6G, Pacific Blue™ anti-mouse Ly-6G, APC anti-mouse Ly-6G, PerCP/Cyanine5.5 anti-mouse Ly-6G, PE/Cyanine7 anti-mouse Ly-6G, Alexa Fluor® 700 anti-mouse Ly-6G, APC/Cyanine7 anti-mouse Ly-6G, Alexa Fluor® 488 anti-mouse Ly-6G, Brilliant Violet 421™ anti-mouse Ly-6G, Brilliant Violet 570™ anti-mouse Ly-6G, Ultra-LEAF™ Purified anti-mouse Ly-6G, Brilliant Violet 510™ anti-mouse Ly-6G, Purified anti-mouse Ly-6G (Maxpar® Ready), Brilliant Violet 650™ anti-mouse Ly-6G, Brilliant Violet 711™ anti-mouse Ly-6G, Brilliant Violet 605™ anti-mouse Ly-6G, Brilliant Violet 785™ anti-mouse Ly-6G, PE/Dazzle™ 594 anti-mouse Ly-6G, APC/Fire™ 750 anti-mouse Ly-6G, PerCP anti-mouse Ly-6G, TotalSeq™-A0015 anti-mouse Ly-6G, TotalSeq™-C0015 anti-mouse Ly-6G, TotalSeq™-B0015 anti-mouse Ly-6G, Spark Blue™ 550 anti-mouse Ly-6G, Spark NIR™ 685 anti-mouse Ly-6G, Spark YG™ 593 anti-mouse Ly-6G, APC/Fire™ 810 anti-mouse Ly-6G Antibody, PE/Cyanine5 anti-mouse Ly-6G, PE/Fire™ 810 anti-mouse Ly-6G Antibody, Spark UV™ 387 anti-mouse Ly-6G, PE/Fire™ 640 anti-mouse Ly-6G

## Product Data

---



C57BL/6 mouse bone marrow cells were stained with Ly-6G (clone 1A8) Brilliant Violet 421™ (filled histogram) or rat IgG2a, κ Brilliant Violet 421™ isotype control (open histogram). Data shown was gated on myeloid cell population.



C57BL/6 mouse frozen spleen section was fixed with 4% paraformaldehyde (PFA) for ten minutes at room temperature and blocked with 5% FBS and 5% rat/mouse serum for one hour at room temperature. Then the section was stained with 2.5 µg/mL of Ly-6G (clone 1A8) Brilliant Violet 421™ (red), 5 µg/mL of CD3 Alexa Fluor® 647 (green), and 5 µg/mL of B220 Alexa Fluor® 488 (blue) overnight at 4°C. The image was captured by 10X objective.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
 Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587